MONTREAL, Jan. 15 /CNW Telbec/ - (TSX.V: BUG). Biophage Pharma Inc. today announced that it has received confirmation of financial support from the National Research Council Industrial Research Assistance Program (NRC-IRAP) for the development of its next generation of PDS(R) Biosensors which will rapidly and specifically detect life threatening pathogens like Methicillin Resistant Staphylococcus Aureus (MRSA), Pseudomonas aeruginosa and E. coli O157.
